Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANGIODYNAMICS INCANGO · Entity 5275 | SVP and GM of Oncology | February 12, 2020 | February 19, 2020 |
| NUVASIVE INCNUVA · Entity 110002 | EVP, Global Commercial | March 01, 2021 | March 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANGIODYNAMICS INC
Report date February 12, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,416 |
Reported balance
After 2020-02-12 transaction · row 1
1 source rowRow 1 · 2020-02-12 · Tax withholding · Disposed 490 · Balance 15,416 F1: The exempt disposition of 490 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 12, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The exempt disposition of 490 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 12, 2018.
NUVASIVE INC
Report date March 01, 2021 · Filed March 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,315 |
Reported balance
After 2021-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-01 · Grant · Acquired 7,315 · Balance 7,315 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: This RSU award was granted to the Reporting Person on March 1, 2021. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: This RSU award was granted to the Reporting Person on March 1, 2021. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 3, 2021 17:53 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 7,315 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017154 · doc4.xml · derivative · entry 1 Boucher Brent J. · CIK 0001766229 · EVP, Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,315 Underlying: Common Stock · 7,315 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2021. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2024. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2021. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2024. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 5,614 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055135 · doc4.xml · derivative · entry 1 Boucher Brent J. · CIK 0001766229 · EVP, Global Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,614 Underlying: Common Stock · 5,614 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on October 14, 2020. In accordance with the terms of the RSU award, the award will vest as to 2,807 shares on each of October 14, 2021 and October 14, 2022. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on October 14, 2020. In accordance with the terms of the RSU award, the award will vest as to 2,807 shares on each of October 14, 2021 and October 14, 2022. Read SEC document |
| February 12, 2020 Filed Feb 19, 2020 00:03 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 490 | $12.99 | $6,365.10 |
DisclosureSEC source: 0001567619-20-004259 · doc1.xml · nonDerivative · entry 1 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,416 F1 · shares: The exempt disposition of 490 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 12, 2018. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:17 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 490 | $15.48 | $7,585.20 |
DisclosureSEC source: 0001567619-20-001294 · doc1.xml · nonDerivative · entry 1 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,906 F1 · shares: The exempt disposition of 490 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on January 17, 2018. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 22:23 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantPerformance Right · Derivative | 6,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-019767 · doc1.xml · derivative · entry 1 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,452 Underlying: Common Stock · 6,452 shares Expires not disclosed F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited. F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited. F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 18, 2019 Filed Jul 25, 2019 20:48 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 148 | $21.53 | $3,186.44 |
DisclosureSEC source: 0001567619-19-015203 · doc1.xml · nonDerivative · entry 2 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,396 F2 · shares: The exempt disposition of 148 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 18, 2019 Filed Jul 25, 2019 20:48 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 225 | $21.53 | $4,844.25 |
DisclosureSEC source: 0001567619-19-015203 · doc1.xml · nonDerivative · entry 1 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,544 F1 · shares: The exempt disposition of 225 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:36 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,790 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001567619-19-015049 · doc1.xml · derivative · entry 2 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,790 Underlying: Common Stock · 10,790 shares Expires 2029-07-17 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:36 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 3,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-015049 · doc1.xml · nonDerivative · entry 1 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,769 F1 · shares: This acquisition of 3,226 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,226 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:14 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 490 | $22.90 | $11,221.00 |
DisclosureSEC source: 0001567619-19-004544 · doc1.xml · nonDerivative · entry 1 Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,543 F1 · shares: The exempt disposition of 490 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 12, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.